Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773 open label
Drug: BI 10773
Drug: BI10773
Drug: Sitagliptin
Drug: Placebo identical to BI10773 low dose
Drug: Placebo identical to Sitagliptin 100mg
Drug: Placebo identical to BI10773 high dose

First Posted Date: 2010-08-09

Last Posted Date: 2014-06-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 986

Registration Number: NCT01177813

Locations: 🇧🇪
1245.20.32016 Boehringer Ingelheim Investigational Site, Deurne, Belgium
🇺🇸
1245.20.10154 Boehringer Ingelheim Investigational Site, Chino, California, United States
🇺🇸
1245.20.10078 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States

and more 121 locations

Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2010-08-03

Last Posted Date: 2014-08-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 571

Registration Number: NCT01174459

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site 94, Toyokawa, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 151, Kumamoto, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 82, Gifu, Japan

and more 156 locations

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: 50 mcg salmeterol HFA MDI
Drug: tiotropium Respimat® low dose
Drug: tiotropium Respimat® high dose

First Posted Date: 2010-07-30

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1071

Registration Number: NCT01172808

Locations: 🇧🇷
205.418.55002 Boehringer Ingelheim Investigational Site, Juiz de Fora, Brazil
🇺🇸
205.418.01004 Boehringer Ingelheim Investigational Site, Coeur d'Alene, Idaho, United States
🇺🇸
205.418.01013 Boehringer Ingelheim Investigational Site, North Dartmouth, Massachusetts, United States

and more 111 locations

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: tiotropium Respimat® high dose
Drug: tiotropium Respimat® low dose
Drug: placebo
Drug: 50 mcg salmeterol HFA MDI

First Posted Date: 2010-07-30

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1032

Registration Number: NCT01172821

Locations: 🇺🇸
205.419.01068 Boehringer Ingelheim Investigational Site, Novi, Michigan, United States
🇺🇸
205.419.01071 Boehringer Ingelheim Investigational Site, Raleigh, North Carolina, United States
🇺🇸
205.419.01056 Boehringer Ingelheim Investigational Site, Union, South Carolina, United States

and more 122 locations

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: BIBF 1120

First Posted Date: 2010-07-27

Last Posted Date: 2019-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 198

Registration Number: NCT01170065

Locations: 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇨🇱
Instituto Nacional del Tórax, Santiago, Chile
🇧🇬
Special. Hospital for Active Treatment, Sv. Sofia 2nd Clinic, Sofia, Bulgaria

and more 54 locations

Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2010-07-27

Last Posted Date: 2014-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 651

Registration Number: NCT01170091

Locations: 🇰🇷
Boehringer Ingelheim Investigational Site 1, Busan, Korea, Republic of
🇰🇷
Boehringer Ingelheim Investigational Site 2, Busan, Korea, Republic of
🇰🇷
Boehringer Ingelheim Investigational Site 35, Daejeon, Korea, Republic of

and more 33 locations

Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ibuprofen
Drug: Pseudoephedrine-HCl

First Posted Date: 2010-07-27

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 47

Registration Number: NCT01170637

Locations: 🇩🇪
1024.7.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992 low dose
Drug: BIBW 2992 high dose 6 day
Drug: BIBW 2992 high dose
Drug: BIBW 2992 medium dose 6 day
Drug: BIBW 2992 medium dose
Drug: BIBW 2992 low dose 6 day
Drug: pemetrexed

First Posted Date: 2010-07-26

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT01169675

Locations: 🇨🇦
1200.92.1001 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦
1200.92.1002 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Glimepiride
Drug: BI 10773
Drug: Placebo

First Posted Date: 2010-07-22

Last Posted Date: 2016-09-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1549

Registration Number: NCT01167881

Locations: 🇦🇹
1245.28.43003 Boehringer Ingelheim Investigational Site, Wien, Austria
🇺🇸
1245.28.10030 Boehringer Ingelheim Investigational Site, Draper, Utah, United States
🇺🇸
1245.28.10014 Boehringer Ingelheim Investigational Site, Rochester, New York, United States

and more 179 locations

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Renal Insufficiency

Interventions: Drug: BI 10773
Drug: Placebo

First Posted Date: 2010-07-16

Last Posted Date: 2014-06-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 741

Registration Number: NCT01164501

Locations: 🇺🇸
1245.36.10014 Boehringer Ingelheim Investigational Site, Anaheim, California, United States
🇺🇸
1245.36.10012 Boehringer Ingelheim Investigational Site, Corpus Christi, Texas, United States
🇳🇱
1245.36.31004 Boehringer Ingelheim Investigational Site, Den Haag, Netherlands

and more 124 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy